

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1-5. (Cancelled)

6. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising, a heavy chain variable domain selected from the group consisting of: SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15, and a light chain variable domain selected from the group consisting of: SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, and SEQ ID No. 19.

Claims 7- 16 (Cancelled)

17. (Currently Amended) A pharmaceutical composition comprising a humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG according to claim 6, further comprising a pharmaceutically acceptable diluent or carrier.

18-26. (Cancelled)

27. (Currently Amended) The humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG according to claim 6, further comprising a constant part or fragment thereof of a human light chain and a constant part or fragment thereof of a human heavy chain.

28. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:
a heavy chain variable region of SEQ ID No. 13 and
a light chain variable region of SEQ ID No. 16.

29. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 13 and
a light chain variable region of SEQ ID No. 17.

30. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 13 and
a light chain variable region of SEQ ID No. 18.

31. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 13 and
a light chain variable region of SEQ ID No. 19.

32. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 14 and
a light chain variable region of SEQ ID No. 16.

33. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 14 and
a light chain variable region of SEQ ID No. 17.

34. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 14 and
a light chain variable region of SEQ ID No. 18.

35. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 14 and

a light chain variable region of SEQ ID No. 19.

36. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 15 and

a light chain variable region of SEQ ID No. 16.

37. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 15 and

a light chain variable region of SEQ ID No. 17.

38. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 15 and

a light chain variable region of SEQ ID No. 18.

39. (Currently Amended) A humanised anti-MAG antibody ~~or functional fragment thereof~~ which binds to and neutralizes MAG comprising:

a heavy chain variable region of SEQ ID No. 15 and

a light chain variable region of SEQ ID No. 19.